4 Pharmas make bid into low-dose statin combo drug mkt

By Lee, Tak-Sun | translator Kang, Shin-Kook

24.05.22 05:08:46

가나다라 0

Yuhan Corp’s ‘Atovamibe Tab 10/5mg’ is the only low-dose statin combo option available in Korea

Products from Daewon Pharmaceutical, Dongkook Pharmaceutical, Daewoong Pharmaceutical, and Boryung Pharmaceutical will be listed for reimbursement next month

The popularity of low-dose statin continues. Due to its lower risk of side effects than high-dose statins and a higher cholesterol-lowering effect when combined with ezetimibe than as monotherapy, domestic pharmaceutical companies have been busy launching low-dose statin combination products one after another.

According to industry sources on the 21st, 4 hyperlipidemia combination drugs that contain low-dose atorvastatin (5 mg) and ezetimibe will be listed for reimbursement in June.

The atorvastatin 5 mg and ezetimibe combination was first introduced by Yuhan Corp in August last year. The drug, AtovamibeTab 10/5mg, was listed at an insurance ceiling price of KRW 637.

Amo

Lee, Tak-Sun(hooggasi2@dailypharm.com)

If you want to see the full article, please JOIN US (click)